We have detected that you are using an Ad Blocker.
PracticeUpdate is free to end users but we rely on advertising to fund our site. Please consider supporting PracticeUpdate by whitelisting us in your ad blocker.
We have sent a message to the email address you have provided, . If this email is not correct, please update your settings with your correct address.
The email address you provided during registration, , does not appear to be valid. Please update your settings with a valid address before to continue using PracticeUpdate.
Please provide your AHPRA Number to ensure that you are given the correct level of access to our site.
Published in Benign Hematology

Journal Scan / Research · January 20, 2022

Response and Survival in Waldenström Macroglobulinemia Treated With Ibrutinib Monotherapy

Blood Advances


Additional Info

Blood Advances
Predictors of response and survival in a large cohort of 319 Waldenström macroglobulinemia patients treated with ibrutinib monotherapy
Blood Adv 2021 Dec 29;[EPub Ahead of Print], JJ Castillo, S Sarosiek, JN Gustine, C Flynn, C Leventoff, TP White, KE Meid, ML Guerrera, A Kofides, X Liu, M Munshi, N Tsakmaklis, ZR Hunter, CJ Patterson, AR Branagan, SP Treon

From MEDLINE®/PubMed®, a database of the U.S. National Library of Medicine.

Further Reading